Uncy Type a Meeting with FDA 2025 - Search Videos

Outlook Therapeutics provides update following Type A meeting with FDA

Outlook Therapeutics provides update following Type A meeting with FDA

marketscreener.com

2025 FDA Financial Public Meeting

2025 FDA Financial Public Meeting

childrenshealthdefense.org

Unicycive Therapeutics (Nasdaq: UNCY) announced that the FDA has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the company’s investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The FDA deemed the resubmission a Class II complete response, resulting in a six-month review period, and assigned a PDUFA target action date of June 29, 2026. Unicycive Therapeutics is a B2i

Unicycive Therapeutics (Nasdaq: UNCY) announced that the FDA has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the company’s investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The FDA deemed the resubmission a Class II complete response, resulting in a six-month review period, and assigned a PDUFA target action date of June 29, 2026. Unicycive Therapeutics is a B2i

3.4K views3 months ago

FacebookB2i Digital

OKYO Pharma clears key FDA meeting for Urcosimod Phase 2b/3 Trial

OKYO Pharma clears key FDA meeting for Urcosimod Phase 2b/3 Trial

Unicycive Therapeutics (Nasdaq: UNCY) announced Q3 2025 results and remains on track to resubmit its NDA for oxylanthanum carbonate (OLC) by year-end. Unicycive Therapeutics is a B2i Digital Featured Company. View their comprehensive profile at https://b2idigital.com/unicycive. The company reported solid progress on multiple fronts, including resolution of FDA manufacturing concerns, presentation of compelling pill burden reduction data at ASN Kidney Week 2025, and a strengthened balance sheet w

155 views6 months ago

FacebookB2i Digital

FDA issues 2025-26 flu vaccine recommendations - WNKY News 40 Television

FDA issues 2025-26 flu vaccine recommendations - WNKY News 40 Television

Unicycive Therapeutics (Nasdaq: UNCY) announced its financial results for the full year ended December 31, 2025, and provided a business update.Unicycive Therapeutics is a B2i Digital Featured… | David Shapiro

Unicycive Therapeutics (Nasdaq: UNCY) announced its financial results for the full year ended December 31, 2025, and provided a business update.Unicycive Therapeutics is a B2i Digital Featured… | David Shapiro

FDA Oncology Drug Approvals 2025 – Archyde

Vaccine advisers to the FDA recommended changes to COVID vaccines

Unicycive Therapeutics (Nasdaq: UNCY) announced that CEO Dr. Shalabh Gupta, MD will be presenting at two September investor conferences. Unicycive Therapeutics is a B2i Digital Featured Company. View their comprehensive profile at https://b2idigital.com/unicycive. - Event: H.C. Wainwright 27th Annual Global Investment Conference, Type: Fireside chat, Date/Time: Wednesday, September 10, 2025, at 8:30 a.m. ET - Event: Truist Securities Virtual Fireside Chat, Date/Time: Wednesday, September 17, 202

1.7K views9 months ago

FacebookB2i Digital

FDA meetings Drug Development process | Regulatory affairs |

2K viewsApr 17, 2022

YouTubeBiology Lectures

Cognition Therapeutics, Inc. Completes Type C Meeting with FDA for Zervimesine in Dementia with Lewy Bodies

marketscreener.com

2025 International Fall Summit - NCODA

News for UNCY

2025 Board and Committee Meetings

FDA Meeting Types

1.5K viewsFeb 13, 2022

YouTubeclevaforce

2025 AIChE Annual Student Conference

Regulatory experts’ guide to a successful FDA meeting

797 viewsDec 5, 2023

YouTubeCardinal Health

Step 3: What are the Types of USFDA Meetings (Part 2)? | Regulatory Learnings | DRA

1K viewsFeb 26, 2022

YouTubePharmaCamp

Vaccines and Related Biological Products Advisory Committee May 22, 2025 Meeting

14.3K viewsMay 22, 2025

YouTubeU.S. Food and Drug Administration

21/12/2025 KEA FDA Communication Question Paper Analysis & || Key Answers With Decoding

25.1K views5 months ago

YouTubeAshwamedha IAS (Sudharshan N R)

Step 3: Meetings with USFDA (Part 1) | Regulatory Learnings | Drug Regulatory Affairs

1.5K viewsFeb 20, 2022

YouTubePharmaCamp

Tobacco Products Scientific Advisory Committee Meeting, October 7, 2025

949 views6 months ago

YouTubeU.S. Food and Drug Administration

Regulatory Affairs Explained Series Episode 2 | Requesting Meetings, Meeting Types, Timelines & More

10.2K viewsJan 19, 2022

YouTubekyyah abdul

Step 3: 10 Tips For Preparation of Successful USFDA Meeting (Part 4)? | Regulatory Learnings | DRA

843 viewsMar 6, 2022

YouTubePharmaCamp

Mid-Review Cycle Meeting Overview

1.2K viewsMay 13, 2021

YouTubeU.S. Food and Drug Administration

U.S. Food and Drug Administration - A Deep Dive: FDA’s Model-Integrated Evidence (MIE) Industry Meeting Pilot Program for Generic Drugs (YouTube)

14 views3 months ago

Internet ArchiveGrumpy Systems

FDA Strategy 2025 Policy, Pressures and the Path to MedTech Clearance | leanRAQA Live

226 views7 months ago

YouTubeleanRAQA

Podcast: Unicycive Therapeutic

10 views6 months ago

YouTubeLevi & Korsinsky

21/12/2025 KEA FDA Question Paper Analysis || Key Answers || Decoding

46.8K views5 months ago

YouTubeAshwamedha IAS (Sudharshan N R)

See more